Regorafenib monohydrate is primarily used in the treatment of certain types of cancer. It is effective in managing metastatic colorectal cancer, gastrointestinal stromal tumors (GIST), and hepatocellular carcinoma (HCC). The compound works by inhibiting multiple kinases involved in tumor growth, angiogenesis, and the tumor microenvironment. This targeted approach helps to slow down the progression of cancer and improve survival rates in patients who have not responded to other treatments. It is typically administered orally, allowing for convenient use in outpatient settings. Regular monitoring is essential to manage potential side effects and ensure optimal therapeutic outcomes.